We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

155 hedge funds and large institutions have $1.86B invested in Kite Pharma, Inc. in 2015 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 62 increasing their positions, 49 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 49

21% more call options, than puts

Call options by funds: $41M | Put options by funds: $34M

5% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 22

2% more capital invested

Capital invested by funds: $1.82B → $1.86B (+$38.7M)

0% more funds holding

Funds holding: 155155 (0)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

Holders
155
Holders Change
Holders Change %
0%
% of All Funds
4.33%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.17%
New
23
Increased
62
Reduced
49
Closed
22
Calls
$41M
Puts
$34M
Net Calls
+$7.03M
Net Calls Change
+$22.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$298M -$8M -127,225 -2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$177M -$5.01M -79,600 -2%
Viking Global Investors
3
Viking Global Investors
Connecticut
$138M +$113M +1,795,246 +265%
WCM
4
Wildcat Capital Management
New York
$131M
Vanguard Group
5
Vanguard Group
Pennsylvania
$118M +$31M +492,684 +30%
JP Morgan Chase
6
JP Morgan Chase
New York
$85.2M -$10.1M -160,262 -9%
BFA
7
BlackRock Fund Advisors
California
$75.1M +$6.37M +101,305 +8%
Capital World Investors
8
Capital World Investors
California
$72.2M -$1.38M -22,000 -2%
State Street
9
State Street
Massachusetts
$50.4M +$2.17M +34,459 +4%
BIT
10
BlackRock Institutional Trust
California
$44.4M +$22.1M +352,073 +79%
BB
11
BB Biotech
Switzerland
$41.8M +$25.2M +400,000 +114%
FCM
12
Frontier Capital Management
Massachusetts
$41.1M -$16.2M -257,538 -26%
Capital International Investors
13
Capital International Investors
California
$40.4M
PHS
14
PFM Health Sciences
California
$38M +$23.5M +373,425 +121%
RIM
15
RS Investment Management
California
$32.5M +$8.62M +137,120 +31%
CGT
16
Capital Guardian Trust
California
$26.2M -$1.23M -19,600 -4%
UBS AM
17
UBS AM
Illinois
$23.4M -$112K -1,782 -0.4%
MMH
18
Menora Mivtachim Holdings
Israel
$22.8M -$5.54M -88,058 -18%
Franklin Resources
19
Franklin Resources
California
$22.7M
AG
20
Artal Group
Luxembourg
$21.7M -$2.2M -35,000 -8%
RI
21
RTW Investments
New York
$20.9M -$1.54M -24,524 -6%
JMPWA
22
JP Morgan Private Wealth Advisors
California
$20.6M -$91.3K -1,451 -0.4%
Northern Trust
23
Northern Trust
Illinois
$17.7M +$11.8M +188,138 +144%
EC
24
EcoR1 Capital
California
$15.7M
American Century Companies
25
American Century Companies
Missouri
$15.1M +$494K +7,851 +3%

KITE Hedge Fund Activity: Q3 2015 in Review

155 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2015, worth a combined $1.86B — up 2.1% from $1.82B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new KITE positions and 22 closed out — a net gain of 1 holder — while 62 added to existing stakes and 49 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $113M. The largest seller was Frontier Capital Management, cutting an estimated $16.2M.

  • 155 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2015, unchanged from Q2 2015.
  • Funds reported $1.86B of Kite Pharma, Inc. stock for Q3 2015, up 2.1% quarter-over-quarter.
  • 23 funds opened new Kite Pharma, Inc. positions in Q3 2015 and 22 closed out, a net change of +1 holder.
  • The largest Kite Pharma, Inc. buyer in Q3 2015 was Viking Global Investors, an estimated $113M added.
  • The largest Kite Pharma, Inc. seller in Q3 2015 was Frontier Capital Management, an estimated $16.2M sold.

Based on aggregated 13F filings for Q3 2015.